Price
Target price
€9.44
€9.44
-0.950%
-0.09
-0.950%
€29.59
23.12.25 / Tradegate
WKN: A12EV9 / Symbol: DVAX / Name: Dynavax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Dynavax Technologies Corp Stock
Dynavax Technologies Corp shows a slight decrease today, losing -€0.090 (-0.950%) compared to yesterday.
Our community is currently high on Dynavax Technologies Corp with 3 Buy predictions and 1 Sell predictions.
Based on the current price of 9.44 € the target price of 29 € shows a potential of 207.07% for Dynavax Technologies Corp which would more than double the current price.
Pros and Cons of Dynavax Technologies Corp in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Dynavax Technologies (NASDAQ:DVAX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for DVAX provided by MarketBeat
Dynavax Technologies Co. (NASDAQ: DVAX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $12.00 to $10.00. They now have a "sell" rating on the stock.
Show more
Ratings data for DVAX provided by MarketBeat
Dynavax Technologies Co. (NASDAQ: DVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.
Show more
Ratings data for DVAX provided by MarketBeat
News
Why Dynavax Stock Soared Today
Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by Sanofi (NASDAQ: SNY).
As of 3:00 p.m. EST, Dynavax's stock price was up
Dynavax (DVAX) Q2 Revenue Jumps 29%
Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4